Heidelberg Pharma AG
HPHA
Rank in Stocks
#19083
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.46
Last synced: 2026-11-09
Market Cap
$114.99M
Change (1 day)
3.02%
Change (1 year)
-32.01%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Heidelberg Pharma AG (HPHA)
Category
Healthcare
Operating Margin for Heidelberg Pharma AG (HPHA)
Operating Margin as of November 2026 TTM: -331.50%
According to Heidelberg Pharma AG's latest financial reports, its current operating margin (TTM) is -331.50%. At the end of 2025 the company had an operating margin of -3,255.36%.
Operating Margin history for Heidelberg Pharma AG from 2006 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -331.50% | -89.82% |
| 2025 | -3,255.36% | 807.92% |
| 2024 | -358.55% | 66.67% |
| 2023 | -215.13% | 117.24% |
| 2022 | -99.03% | -93.24% |
| 2021 | -1,464.78% | 569.74% |
| 2020 | -218.71% | 54.24% |
| 2019 | -141.80% | -55.44% |
| 2018 | -318.21% | -43.77% |
| 2017 | -565.93% | 21.17% |
| 2016 | -467.04% | 63.70% |
| 2015 | -285.31% | 84.04% |
| 2014 | -155.03% | 315.96% |
| 2013 | -37.27% | -25.37% |
| 2012 | -49.94% | -63.14% |
| 2011 | -135.49% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -128.64% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.55% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.09% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Heidelberg Pharma AG's operating margin
What is Heidelberg Pharma AG's operating margin?
Heidelberg Pharma AG's operating margin is -331.50%, as of Nov 2026.
What was Heidelberg Pharma AG's operating margin in 2025?
In 2025, Heidelberg Pharma AG's operating margin was -3,255.36%, compared with -358.55% in 2024.
How has Heidelberg Pharma AG's operating margin changed since 2020?
From 2020 to 2025, Heidelberg Pharma AG's operating margin was highest in 2022 (-99.03%) and lowest in 2025 (-3,255.36%).
How does Heidelberg Pharma AG's operating margin compare with similar companies?
Heidelberg Pharma AG's operating margin (-331.50%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.